Mereo BioPharma (MREO) Other Non-Current Assets (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Other Non-Current Assets of $387000.0 for Q1 2026, up 1.84% year-over-year from $380000.0 in Q1 2025, and down 2.03% quarter-over-quarter from $395000.0 in Q4 2025.
Mereo BioPharma (MREO) Other Non-Current Assets (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Other Non-Current Assets for 4 consecutive years, with $387000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 1.84% year-over-year to $387000.0; the TTM figure through Mar 2026 stood at $387000.0 (up 1.84% YoY), while the FY2025 annual figure was $395000.0, up 4.5% from the prior year.
- Other Non-Current Assets fell to $387000.0 in Q1 2026 per MREO's latest filing, from $395000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $615000.0 in Q4 2023 and bottomed at $378000.0 in Q4 2024.
- Historically, Other Non-Current Assets has averaged $429222.2 across 4 years, with a median of $395000.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets tumbled 38.54% — and 2025, when it advanced 4.5%.
- Mereo BioPharma's Other Non-Current Assets stood at $615000.0 in 2023, then sank by 38.54% to $378000.0 in 2024, then gained by 4.5% to $395000.0 in 2025, then decreased by 2.03% to $387000.0 in 2026.
- Business Quant data shows MREO's Other Non-Current Assets at $387000.0 in Q1 2026, $395000.0 in Q4 2025, and $394000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | 388,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 388,000.00 |
| Mar 31, 2026 | 387,000.00 |
| Dec 31, 2025 | 395,000.00 |
| Sep 30, 2025 | 394,000.00 |
| Jun 30, 2025 | 402,000.00 |
| Mar 31, 2025 | 380,000.00 |
| Dec 31, 2024 | 378,000.00 |
| Sep 30, 2024 | 437,000.00 |
| Jun 30, 2024 | 475,000.00 |
| Dec 31, 2023 | 615,000.00 |